Disappearance of vaccine-type invasive pneumococcal disease and emergence of serotype 19A in a minority population with a high prevalence of human immunodeficiency virus and low childhood immunization rates.
We analyzed the epidemiology of invasive pneumococcal disease (IPD) following introduction of pneumococcal conjugated vaccine in an urban population with a 2% human immunodeficiency virus (HIV) prevalence and history of low childhood immunization rates. We observed near-elimination of vaccine-type IPD. Substantial disease remains due to non-vaccine-type pneumococci, highlighting the need to increase pneumococcal immunization among HIV-infected adults.
Tasslimi
Azadeh
A
Department of Preventive Medicine and Community Health, New Jersey Medical School-UMDNJ, MSB F594, Newark, NJ 07103, USA.
Sison
Erica J
EJ
Story
Elizabeth
E
Alland
David
D
Burday
Michele
M
Morrison
Susan
S
Nalmas
Sandhya
S
Smith
Stephen
S
Thomas
Pauline A
PA
Wenger
Peter
P
Sinha
Anushua
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002675:Child, Preschool; D005260:Female; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D011008:Pneumococcal Infections / Q000453:epidemiology* / Q000382:microbiology*; D022242:Pneumococcal Vaccines / Q000276:immunology*; D015995:Prevalence; D012703:Serotyping; D013296:Streptococcus pneumoniae / Q000145:classification* / Q000276:immunology / Q000302:isolation & purification*; D014481:United States; D014505:Urban Population; D055815:Young Adult
D022242:Pneumococcal Vaccines